# Effects of Rivaroxaban on Vascular FMD in Patients With Stable Atherosclerotic Vascular Diseases

> **NCT06986369** · PHASE4 · COMPLETED · sponsor: **The University of Hong Kong** · enrollment: 140 (actual)

## Conditions studied

- Atherosclerosis, Coronary

## Interventions

- **DRUG:** Rivaroxaban 2.5 MG Oral Tablet [Xarelto]

## Key facts

- **NCT ID:** NCT06986369
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-04
- **Primary completion:** 2023-08-28
- **Final completion:** 2024-03-01
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2025-05-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06986369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06986369, "Effects of Rivaroxaban on Vascular FMD in Patients With Stable Atherosclerotic Vascular Diseases". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06986369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*